Improved Method for the Determination of Residual Aminoglycoside Antibiotics in Animal Tissues by Electrophoresis and Bioautography

Total Page:16

File Type:pdf, Size:1020Kb

Improved Method for the Determination of Residual Aminoglycoside Antibiotics in Animal Tissues by Electrophoresis and Bioautography 96 Journal of Food Protection, Vol 52, No. 2, Pages 96-99 (February 1989) Copyright© International Association ot Milk, Food and Environmental Sanitarians Improved Method for the Determination of Residual Aminoglycoside Antibiotics in Animal Tissues by Electrophoresis and Bioautography FUSAO KONDO* and SACHIKO HAYASHI Department of Veterinary Public Health, Faculty of Agriculture, Miyazaki University, I, l-chome, Kibanadai-nishi, Gakuen, Downloaded from http://meridian.allenpress.com/jfp/article-pdf/52/2/96/1655464/0362-028x-52_2_96.pdf by guest on 28 September 2021 Miyazaki-shi, Japan 889-21 (Received for publication July 19, 1988) ABSTRACT bioautographic visualization of the separated components has been reported by several authors (1,2,3,4,7,9,11,12,15). The use of agar gel electrophoresis and bioautography for Most of these methods involve the application of antibi­ the identification of small amounts of seven aminoglycoside otic solutions of high potency. In order to obtain a more antibiotics (streptomycin, dihydrostreptomycin, kanamycin, sensitive method, the procedure described by Lightbown bekanamycin, gentamicin, fradiomycin and paromomycin) was and Rossi (4) was evaluated. After agar gel electrophoresis, studied. The procedure used for the electrophoretic separation of these components is described. The antibiotics were detected the gel was covered with a second layer of agar seeded with high sensitivity using Bacillus subtilis ATCC 6633 as a test with a test organism. However, they reported difficulty in organism, Tris buffer at pH 8.0, and Bacto-Agar as the support­ obtaining thin layers of uniform thickness due to larger gel ing medium for each of the components. The limits of detection tray (94 x 19 cm), which is a prerequisite for high repro­ obtained for the various antibiotics ranged between 0.078 and ducibility and sensitivity. Because of the long duration of 0.313 ug/ml and the standard deviation ranged from 0.05 and electrophoresis ( 1 to 3 h), growth of contaminants often 0.34. Recoveries from extracts of bovine kidney tissue contain­ occurred. Many previous reports on TLC and bioautogra­ ing each drug ranged from 59.0% to 90.2%. The sensitivity of phy have dealt with a limited number of different antibi­ this method can be adjusted through minor modifications, thus otics, but no studies have focused on antibiotics having a allowing it to be used for routine residual analysis of aminogly­ cosides in biological samples. similar chemical structure. The method described in this paper involves a 40-min period of electrophoresis and permits the identification of up to seven aminoglycoside antibiot­ Aminoglycoside antibiotics (AGs) show stronger anti­ ics. Better sensitivity was obtained than that described in bacterial activity against Gram-negative bacteria in com­ the literature. parison with Gram-positive microorganisms (5) and they are extensively used for the treatment and prevention of MATERIALS AND METHODS infections in livestock. However, this group of drugs are Antibiotics examined known to show high long-term residual concentrations in The aminoglycoside antibiotics studied and their source: the kidney in comparison with other antibiotics (6). For streptomycin (SM), and dihydrostreptomycin (DSM) (Meiji Seika this reason, a 30-d drug-clearance period for cows and Co., Tokyo, Japan), kanamycin (KM) and bekanamycin (BKM) pigs is stipulated in Japan. Accordingly, the inspection of (Takeda Chemical Industries, Osaka, Japan), gentamicin (GM) residual aminoglycosides in animal tissues must be inten­ (Sigma Chemical Co., St. Louis, MO), and fradiomycin (FM) sified. and paromomycin (PRM) (the National Veterinary Assay Labo­ There have been many reports on microbioassay (10), ratory, Tokyo, Japan). thin-layer chromatography (TLC), TLC/bioautography (7), Aqueous solutions of each drug were prepared at suitable and gas-liquid chromatography (GLC) (8,16,17) as the ana­ concentrations by dilution in electrolyte. lytical methods for AGs. In the TLC method it is difficult for AGs to be visualized on the TLC plate using standard Culture Media Heart infusion broth (HIB; Difco Laboratories, Detroit, MI) developing solvent. On the other hand, specimens for GLC was used for preculture of the test organism and Antibiotic Medium analysis must be initially converted chemically to volatile No. 1 (AMI; Difco) was used as the layer medium after addition substances. Measurement of AGs by enzyme immunoas­ of 1.5% Bacto Agar (Difco). say has also been reported (13,14), but this method is not yet in general use. Bacteria The separation of antibiotics by TLC followed by Bacillus subtillis ATCC 6633 was used as the test organ- JOURNAL OF FOOD PROTECTION, VOL. 52, FEBRUARY 1989 DETERMINATION OF ANTIBIOTICS IN ANIMAL TISSUES 97 ism. The culture medium was inoculated with B. subtilis cells to water bath at 70 to 80°C. After centrifuging for 10 min at 900 achieve a concentration of 104 cfu/ml in the layer medium (AMI). G, the supernatant was placed in a rotary flask and evaporated The size of the gels poured was 60 x 25 x 0.2 cm. to dryness under reduced pressure at 70°C using a rotary evapo­ rator. After dissolving the residue with a small amount of phosphate Electrophoresis equipment buffer, the sample was passed through a filter paper, Toyo Roshi The DNA Sub Cell Electrophoresis System 170-4304 (Bio- Type No. 2, (Toyo Roshi Kaisya, Ltd., Tokyo). The filtrate was Rad Laboratories, Milano, Italy) with a Model Elepos PS-2515 further passed through a Sep-Pak silica cartridge (Waters Asso­ (Toyo Kagaku Sangyo Ltd., Tokyo) power pack capable of ciates, Inc., Milford, MA) and the cartridge washed with 5 ml delivering a maximum current of 200 mV or 2500 volts was of distilled water. Next, elution was performed with 4 ml of used for electrophoresis. The electrophoresis gel plate was connected 10% acetic acid, and the eluate was dried and condensed by to a "Neocool", model BP-51 aspirator (Yamato Instruments spraying with nitrogen gas. The sediment was finally dissolved Co., Tokyo, Japan) for cooling at 5°C. with 1 ml of distilled water and used for the electrophoresis. Electrolytes RESULTS The electrolytes used were buffers containing (g/1): Tris, Downloaded from http://meridian.allenpress.com/jfp/article-pdf/52/2/96/1655464/0362-028x-52_2_96.pdf by guest on 28 September 2021 1.82, succinic acid, 0.98; pH 6.0; and Tris, 3.03; succinic acid, Effect of migration to supporting media and electrolytes 0.85; pH 8.0, prepared from analytical-grade reagents. Various The results for the migration distance and direction of phosphate buffers at 1/15 M were also prepared to give pH mobility of AGs, when Tris and phosphate buffer were values of 6.5, 7.0, 7.5 and 8.0 with 0.1 N phosphoric acid or 0.1 used as electrolytes, are shown in Tables 1 and 2, respec­ N sodium hydroxide, respectively. These electrolytes were also used as solvents for the supporting media. tively. AGs generally migrated further in Bacto Agar than in Agar Noble. All drugs moved in the direction of the Supporting media anode in Tris buffer at both pH values in the Bacto Agar. The supporting gels were 1% (w/v) Bacto Agar (Difco) and However, it differed depending on the antibiotics present 1% (w/v) Agar Noble (difco) prepared independently after dis­ in the Agar Noble (Table 1). GM did not move at all in solving in the two buffers used as electrolytes, according to the the Agar Noble and Tris buffer, pH 8.0. All drugs moved method of Smither and Vaughan (II). in the direction of the cathode, irrespective of pH, when After cooling to 50°C, the agar gels were poured onto the phosphate buffer was used as the electrolyte (Table 2). leveled gel plate to give a uniform gel depth of 2.0 mm. When B. subtilis was used as the test organism in phos­ phate buffer, no growth on several plates sometimes occurred. Electrophoresis procedure Accordingly, it was judged that phosphate buffer was not Ten microliters of each diluted drug solution was infused a good electrolyte. onto a spot on the gel plate, using the same buffer as that employed to prepare the plate. After setting, the gel layers were connected to the electrolyte in the buffer boxes by a layer of thick cotton Detection limits and migration distance of aminoglyco­ fabric. After closing the lid of the safety box, the electrophoresis sides was normally run for 40 min at a constant current of 190 mA, When analysis of the drugs was carried out using Tris which gave a starting potential of 800 volts. During the electro­ buffer and Bacto Agar, the detection limit of each drug phoresis, water at 5°C from the cooling aspirator was run under ranged from 0.313 to 5.0 |ig/ml at pH 6.0 and from 0.078 the plate bed to prevent the occurrence of so-called joule heat. to 0.313 Ug/ml at pH 8.0, respectively. The detection limit After electrophoresis, Antibiotic Medium No. 1 containing was smaller in the alkaline buffer at pH 8.0 (Table 3). The B. subtilis was layered 0.2 cm thick over the gel plate asepti- cally into a germ-free box and the plates were incubated over­ 4-times-average migration distance of the drugs ranged night at 37°C. Then, by precisely measuring the length of central from 21.8 to 109.1 mm under the analytical conditions of inhibition zone that appeared no growth from a center of each pH 8.0, Tris buffer and Bacto Agar. The standard devia­ drug spot, the migration distance of each drug was determined. tion among the seven drugs ranged from 0.05 to 0.34 (Table The direction of migration and also the forms of the inhibition 4).
Recommended publications
  • Pharmaceutical Applications Notebook
    Pharmaceutical Applications Notebook Antibiotics Table of Contents Index of Analytes .......................................................................................................................................................................3 Introduction to Pharmaceuticals ................................................................................................................................................4 UltiMate 3000 UHPLC+ Systems .............................................................................................................................................5 IC and RFIC Systems ................................................................................................................................................................6 MS Instruments .........................................................................................................................................................................7 Chromeleon 7 Chromatography Data System Software ..........................................................................................................8 Process Analytical Systems and Software ................................................................................................................................9 Automated Sample Preparation ..............................................................................................................................................10 Analysis of Antibiotics ...........................................................................................................................................................11
    [Show full text]
  • G Genito Urinary System and Sex Hormones
    WHO/EMP/RHT/TSN/2018.2 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Learning clinical pharmacology with the use of INNs and their stems. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.2). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
    [Show full text]
  • P147-Bioorgchem-Kanamycin Nucleotidyltransferase-1999.Pdf
    Bioorganic Chemistry 27, 395±408 (1999) Article ID bioo.1999.1144, available online at http://www.idealibrary.com on Kinetic Mechanism of Kanamycin Nucleotidyltransferase from Staphylococcus aureus1 Misty Chen-Goodspeed,* Janeen L. Vanhooke,² Hazel M. Holden,² and Frank M. Raushel*,2 *Department of Chemistry, Texas A&M University, College Station, Texas 77843; and ²Department of Biochemistry, Institute for Enzyme Research, University of Wisconsin, Madison, Wisconsin 53705 Received December 16, 1998 Kanamycin nucleotidyltransferase (KNTase) catalyzes the transfer of the adenyl group from MgATP to either the 4Ј or 4Љ-hydroxyl group of aminoglycoside antibiotics. The steady state kinetic parameters of the enzymatic reaction have been measured by initial velocity, product, and dead-end inhibition techniques. The kinetic mechanism is ordered where the antibiotic binds prior to MgATP and the modified antibiotic is the last product to be released. The effects of altering the relative solvent viscosity are consistent with the release of the products as the rate-limiting step. The pH profiles for Vmax and V/KATP show that a single ionizable group with apK of ϳ8.9 must be protonated for catalysis. The V/K profile for kanamycin as a function of pH is bell-shaped and indicates that one group must be protonated with a pK value of 8.5, while another group must be unprotonated with a pK value of 6.6. An analysis of the kinetic constants for 10 different aminoglycoside antibiotics and 5 nucleotide triphosphates indicates very little difference in the rate of catalysis or substrate binding among these substrates. ᭧ 1999 Academic Press Key Words: kanamycin nucleotidyltransferase; antibiotic modification.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • THALMUUNTURUS009732370B2 (12 ) United States Patent (10 ) Patent No
    THALMUUNTURUS009732370B2 (12 ) United States Patent (10 ) Patent No. : US 9 , 732 , 370 B2 Jagesar ( 45 ) Date of Patent: Aug. 15, 2017 ( 54 ) METHOD FOR THE DETERMINATION OF ( 58 ) Field of Classification Search THE PRESENCE OF AN ANTIBIOTIC IN A None FLUID See application file for complete search history. (71 ) Applicant: DSM IP ASSETS B . V ., Heerlen (NL ) ( 56 ) References Cited ( 72 ) Inventor : Dhiredj Chandre Jagesar , Echt (NL ) U . S . PATENT DOCUMENTS 2007/ 0092929 A1* 4 / 2007 Dekker .. .. .. C12Q 1/ 18 ( 73 ) Assignee : DSM IP ASSETS B . V ., Heerlen (NL ) 435 / 32 ( * ) Notice : Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U . S .C . 154 (b ) by 0 days . EP 0005891 A112 / 1979 EP 0285792 Al 10 / 1988 ( 21) Appl. No .: EP 0611001 AL 8 / 1994 14 /787 , 859 EP 1639122 A1 3 /2006 WO 2005005655 AL 1 / 2005 ( 22 ) PCT Filed : Apr. 30 , 2014 wo 2013057182 AL 4 /2013 ( 86 ) PCT No . : PCT/ EP2014 / 058778 OTHER PUBLICATIONS $ 371 (c ) ( 1 ) , ( 2 ) Date : Oct. 29 , 2015 International Search Report from corresponding PCT/ EP2014 / 058778 , mailed Jul . 23 , 2014 . Gilbertson et al. , “ Modified Microbiological Method for the Screen ( 87 ) PCT Pub . No . : WO2014 / 177597 ing of Antibiotics in Milk ” , 1995 , J. Dairy Sci , vol. 78 , PCT Pub . Date : Nov . 6 , 2014 XP27050235, pp . 1032 - 1038 . (65 ) Prior Publication Data * cited by examiner US 2016 / 0076071 A1 Mar . 17 , 2016 Primary Examiner — Kade Ariani ( 30 ) Foreign Application Priority Data (74 ) Attorney , Agent, or Firm - McBee Moore Woodward & Vanik IP , LLC ; Susan McBee ; Chester May 2 , 2013 (EP ) .
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • 1 Revealing SARS-Cov-2 Functional Druggability Through Multi-Target
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 11 May 2020 doi:10.20944/preprints202005.0199.v1 Revealing SARS-CoV-2 Functional Druggability Through Multi-Target Cadd Screening of Repurposable Drugs Yash Gupta1,2, Dawid Maciorowski1,3, Raman Mathur1, Catherine M Pearce1, David J. IIc1,3, Hamza Husein1,3, Ajay Bharti4, Daniel P. Becker3, Brijesh Rathi2,5, Steven B Bradfute6, Ravi Durvasula1,2, Prakasha Kempaiah1,2* 1 Loyola University Chicago Stritch School of Medicine, Chicago, IL, 60153, USA; 2 Department of Medicine, Loyola University Medical Center, Chicago, IL, 60153, USA; 3 Loyola University Chicago, Chicago, IL, USA; 4 Division of Infectious Diseases, Department of Medicine, University of California, San Diego, CA, 92093, USA, 5 Laboratory for Translational Chemistry and Drug Discovery, Hansraj College, University of Delhi, India; 6 Center for Global Health, Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA. Number of Tables: 10; Number of Figures: 16 ABSTRACT: The emergence of SARS/MERS drug resistant COVID-19 with high transmission and mortality has recently been declared a deadly pandemic causing economic chaos and significant health problems. Like all coronaviruses, SARS-CoV-2 is a large virus that has many druggable components within its proteome. In this study, we focused on repurposing approved and investigational drugs by identifying potential drugs that are predicted to effectively inhibit critical enzymes within SARS-CoV-2. We shortlisted seven target proteins with enzymatic activities known to be essential at different stages of the virus life cycle. For virtual screening, the energy minimization of a crystal structure or modeled protein was carried out using Protein Preparation Wizard (Schrödinger LLC, 2020-1).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Determinants of Aminoglycoside-Binding Specificity for Rrna by Using Mass Spectrometry (16S RNA͞18S Rna͞fourier Transform Ion Cyclotron Resonance Ms͞aminoglycoside)
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 10129–10133, August 1999 Biophysics Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry (16S RNA͞18S RNA͞Fourier transform ion cyclotron resonance MS͞aminoglycoside) RICHARD H. GRIFFEY*, STEVEN A. HOFSTADLER,KRISTIN A. SANNES-LOWERY,DAVID J. ECKER, AND STANLEY T. CROOKE Ibis Therapeutics, a Division of Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, CA 92008 Communicated by Klaus Biemann, Massachusetts Institute of Technology, Cambridge, MA, July 7, 1999 (received for review May 25, 1999) ABSTRACT We have developed methods for studying the unique advantages for rapid characterization of RNA binding interactions between small molecules and RNA and have with aminoglycosides or any chemical or biological substrate. applied them to characterize the binding of three classes of Mixtures of compounds can be screened in parallel with a aminoglycoside antibiotics to ribosomal RNA subdomains. high-resolution Fourier transform ion cyclotron resonance High-resolution MS was used to quantitatively identify the (FT-ICR) mass spectrometer, because the exact molecular noncovalent binding interactions between mixtures of amino- mass of each ligand serves as a unique intrinsic label. Because glycosides and multiple RNA targets simultaneously. Signal ESI-MS measurements are performed from solutions of the overlap among RNA targets was avoided by the addition of RNA(s) and small molecules, the relative concentrations of the neutral mass tags that direct each RNA target to a unique components and buffers can be adjusted to determine binding region of the spectrum. In addition to determining binding constants over a broad range of conditions (13–15). The affinities, the locations of the binding sites on the RNAs were location of binding has been ascertained with ESI-MS͞MS identified from a protection pattern generated by fragmenting protection experiments performed selectively on ions from the ͞ the aminoglycoside RNA complex.
    [Show full text]
  • Bekanamycin | Medchemexpress
    Inhibitors Product Data Sheet Bekanamycin • Agonists Cat. No.: HY-B1174 CAS No.: 4696-76-8 Molecular Formula: C₁₈H₃₇N₅O₁₀ • Molecular Weight: 483.51 Screening Libraries Target: Bacterial; Antibiotic Pathway: Anti-infection Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro H2O : ≥ 100 mg/mL (206.82 mM) DMSO : 1 mg/mL (2.07 mM; ultrasonic and warming and heat to 80°C) * "≥" means soluble, but saturation unknown. Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 2.0682 mL 10.3410 mL 20.6821 mL Stock Solutions 5 mM 0.4136 mL 2.0682 mL 4.1364 mL 10 mM 0.2068 mL 1.0341 mL 2.0682 mL Please refer to the solubility information to select the appropriate solvent. BIOLOGICAL ACTIVITY Description Bekanamycin (Kanamycin B) is an aminoglycoside antibiotic produced by Streptomyces kanamyceticus, against an array of Gram-positive and Gram-negative bacterial strain[1][2]. In Vitro Bekanamycin (Kanamycin B) is a precursor for semisynthetic antibiotics such as Arbekacin and Dibekacin and is generally extracted from the broth of S. kanamyceticus[2]. Bekanamycin (Kanamycin B) in a concentration-dependent fashion reduces reversibly the quantal content of the end-plate potentials while it has no observable effect on the configuration of the extracellularly recorded presynaptic action potential. The reduction in evoked transmitter release produced by Bekanamycin could be antagonized either by increasing the external calcium concentration or by drugs like the aminopyridines which are to greatly enhance transmitter release from motor nerve terminals.
    [Show full text]
  • Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
    TECHNICAL DOCUMENT Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3, ECDC PPS 2016–2017 Suggested citation: European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. Stockholm: ECDC; 2016. Stockholm, October 2016 ISBN 978-92-9193-993-0 doi 10.2900/374985 TQ-04-16-903-EN-N © European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged. ii TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 Contents Abbreviations ............................................................................................................................................... vi Background and changes to the protocol .......................................................................................................... 1 Objectives ..................................................................................................................................................... 3 Inclusion/exclusion criteria .............................................................................................................................. 4 Hospitals .................................................................................................................................................
    [Show full text]
  • United States Patent (19) 11) 4,250,169 Hosoi Et Al
    United States Patent (19) 11) 4,250,169 Hosoi et al. (45) Feb. 10, 1981 54 METHOD OF PRODUCING ANTIBIOTICS 56) References Cited SUPPOSITORIES U.S. PATENT DOCUMENTS 2,854,378 9/1958 Buckwalter .......................... 424/271 75 Inventors: Kaoru Hosoi; Tadamasa Ikeda, both 2,931,798 4/1960 Umezawa et al. ................... 424/8 of Yokohama; Takemi Nakayoshi, 2,975,099 3/1961 Goyan et al. ... ... 424/18 Kawasaki; Akira Okada, Zushi, all of Japan 3,325,472 6/1967 Sackler ................................. 424/227 FOREIGN PATENT DOCUMENTS 73) Assignee: Meiji Seika Kaisha Ltd., Japan 1915191 10/1969 Fed. Rep. of Germany ........... 424/114 OTHER PUBLICATIONS (21) Appl. No.: 45,967 The Merck Index, 9th Ed. (1976), #2969. 22 Filed: Jun. 6, 1979 Primary Examiner-allen J. Robinson Attorney, Agent, or Firm-John J. McGlew Related U.S. Application Data 57 ABSTRACT 63 Continuation of Ser. No. 870,524, Jan. 18, 1978, aban A method of producing aminoglycoside antibiotics in doned. the form of suppositories which comprises dispersing an aminoglycoside antibiotic substance or its non-toxic salts in an oleaginous or aqueous base to which at least 30 Foreign Application Priority Data . a nonionic surface-active agent and/or an anionic sur Jan. 21, 1977 (JP) Japan .................................... 52-4854 face active agent are added and forming said substances with said base into a pharmaceutically safe and effective 51) Int, C. ...................... A61K 31/70; A61K 31/71 suppository for using in living animals and humans, e.g. 52 U.S. C. .................................... 424/181; 424/180; in infants. 424/0IG, 15 58 Field of Search ...............
    [Show full text]